Every Form 4 that Achieve Life Sciences, Inc. (ACHV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ACHV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACHV filings page.
For ACHIEVE LIFE SCIENCES, INC. (ACHV), director Richard Alistair Stewart reported selling 20,626 shares of Common Stock on August 19, 2026 in an open-market transaction at a weighted average price of $8.493 per share, with individual sale prices ranging from $8.4536 to $8.52. Following the sale, he directly holds 208,249 shares and has additional indirect holdings of 359 shares held by his spouse and 882 shares held by Ricanto Limited, of which he is the principal owner.
Achieve Life Sciences director Thomas Sellig received equity awards comprising 25,000 stock options with an exercise price of $6.18 per share and 16,700 restricted stock units (RSUs), each RSU representing one share of common stock.
Both the options and RSUs vest 100% on the earlier of July 27, 2027 or the date immediately prior to Achieve Life Sciences’ 2027 annual meeting of stockholders, contingent on his continued service.
Achieve Life Sciences director Christopher Nathan received equity compensation on July 27, 2026, consisting of stock options for 25,000 shares with a $6.18 exercise price expiring July 27, 2036, and 16,700 RSUs. Both awards vest 100% on the earlier of July 27, 2027 or immediately before the 2027 annual meeting, subject to continued service.
Achieve Life Sciences, Inc. director Aaron Royston reported equity compensation awards effective July 27, 2026. He received stock options for 25,000 shares at a $6.18 exercise price, expiring July 27, 2036, and 16,700 RSUs. Both awards vest 100% on the earlier of July 27, 2027 or immediately before the 2027 annual stockholders meeting, subject to continued service. The options and RSUs are held for the benefit of venBio Global Strategic Fund V, L.P., with related proceeds remitted to that fund, and Royston disclaims beneficial ownership except for his pecuniary interest.
Waldman Reid Alexander reported acquisition or exercise transactions in this Form 4 filing.
Achieve Life Sciences, Inc. director Reid Alexander Waldman received equity compensation on July 27, 2026, consisting of 25,000 stock options to buy common stock at $6.18 per share, expiring July 27, 2036, and 16,700 RSUs. Both awards vest 100% on the earlier of July 27, 2027 or immediately prior to the 2027 annual meeting, subject to continued service.
Achieve Life Sciences director Stewart Richard Alistair received equity awards on July 27, 2026: stock options for 25,000 shares at an exercise price of $6.18 per share and 16,700 RSUs, each RSU settling into one share. Both awards vest 100% on the earlier of July 27, 2027 or immediately before the 2027 annual meeting of stockholders, subject to continued service, resulting in direct holdings of 25,000 options and 16,700 RSUs. The options expire on July 27, 2036.
Achieve Life Sciences, Inc. granted director Jeffrey S. Farrow equity awards consisting of 25,000 stock options to buy common stock at an exercise price of $6.18 per share, expiring July 27, 2036, and 16,700 RSUs. Both the options and RSUs vest 100% on the earlier of July 27, 2027 or the date immediately prior to the company’s 2027 annual meeting of stockholders, subject to Farrow’s continued service.
Achieve Life Sciences director Nancy R. Phelan received new equity awards. She was granted stock options for 25,000 shares of common stock at an exercise price of $6.18 per share, expiring on July 27, 2036. These options vest 100% on the earlier of July 27, 2027 or immediately before the company’s 2027 annual stockholders’ meeting, subject to her continued service. She also received 16,700 Restricted Stock Units, each representing a contingent right to receive one share of common stock, with the same cliff-vesting schedule and service condition.
Achieve Life Sciences director Reid Alexander Waldman received a new stock option grant, giving him the right to buy 47,250 shares of common stock at an exercise price of $5.24 per share. These options vest in substantially equal monthly installments over 36 months starting on May 29, 2026, so the award becomes available gradually as he continues serving the company.
The options expire on May 29, 2036 if not exercised, and this grant brings Waldman’s total reported option holdings from this award to 47,250 derivative securities. The transaction is compensation-related rather than an open-market purchase or sale of existing shares.
ACHIEVE LIFE SCIENCES, INC. reported that director Jeffrey S. Farrow received a grant of stock options. The award covers 47,250 shares of common stock at an exercise price of $5.24 per share, expiring on May 29, 2036. Following the grant, he holds options for 47,250 underlying shares. The options will vest in substantially equal monthly installments over 36 months starting May 29, 2026, as long as he continues providing services to the company on each vesting date.
ACHIEVE LIFE SCIENCES, INC. director Martin Christopher Nathan received a grant of stock options covering 47,250 shares of Common Stock. The options have an exercise price of $5.59 per share and expire on May 11, 2036.
The award was provided as compensation and is held directly. According to the terms, the option will vest in substantially equal monthly installments over 36 months starting on May 11, 2026, as long as Nathan continues to provide service to the company on each vesting date.
ACHIEVE LIFE SCIENCES, INC. granted CEO and President Andrew D. Goldberg three equity awards tied to the company’s common stock. He received 11,706,270 Performance Restricted Stock Units (PRSUs), 3,601,929 stock options with a $4.25 exercise price, and 1,800,965 time-based Restricted Stock Units (RSUs).
The RSUs vest as to one quarter of the award on the one-year anniversary of April 18, 2026 and then in substantially equal quarterly installments over the next twelve quarters, subject to continued service and potential accelerated vesting under his employment agreement. The options vest one quarter on the one-year anniversary of April 18, 2026 and then in substantially equal monthly installments over thirty-six months, also subject to continued service and potential acceleration.
The PRSUs vest based on eight share price milestones ranging from 2x to 9x of a reference price, together with specified financial performance conditions, with eligibility for accelerated vesting under his employment agreement. Each RSU and PRSU represents a contingent right to receive one share of common stock upon settlement.
Achieve Life Sciences Chief Medical Officer receives a new stock option grant. On January 28, 2026, Mark Lawrence Rubinstein was awarded stock options covering 180,000 shares of Achieve Life Sciences common stock at an exercise price of $4.36 per share.
The option will vest as to one quarter of the total award on the first anniversary of January 28, 2026, then in substantially equal monthly installments over the following 36 months, as long as he continues providing service to the company on each vesting date.
Achieve Life Sciences Chief Financial Officer granted 180,000 stock options. The Form 4 reports that CFO Mark K. Oki received a stock option to buy 180,000 shares of common stock at an exercise price of $4.36 per share.
The option vests as to one quarter of the total award on the first anniversary of January 28, 2026, then in substantially equal monthly installments over the following 36 months, as long as he continues providing service to the company on each vesting date.
Achieve Life Sciences, Inc. granted Chief Commercial Officer Jaime Xinos a stock option for 180,000 shares of common stock on January 28, 2026. The option has an exercise price of $4.36 per share.
One quarter of the award will vest on the first anniversary of January 28, 2026, with the remaining shares vesting in substantially equal monthly installments over the following 36 months, contingent on continued service. After the grant, Xinos beneficially owned 180,000 derivative securities directly.
Achieve Life Sciences, Inc. reported a new equity award for Chief Operations Officer Craig Donnelly. He received a stock option to buy 180,000 shares of common stock at an exercise price of $4.36 per share, dated January 28, 2026.
The option vests as to one-quarter of the total award on the first anniversary of January 28, 2026, then in substantially equal monthly installments over the following 36 months, contingent on his continued service. After this grant, Donnelly beneficially owns 180,000 stock options directly.
Achieve Life Sciences chief executive Richard Alistair Stewart received a new stock option grant covering 645,000 shares of common stock. The options have an exercise price of $4.36 per share and expire on January 28, 2036.
According to the filing, one quarter of the award will vest on the first anniversary of January 28, 2026, with the remaining options vesting in substantially equal monthly installments over the following 36 months, contingent on Stewart continuing to provide service to the company on each vesting date.
Achieve Life Sciences, Inc. reported that Principal Accounting Officer Jerry Wan received a grant of stock options for 70,300 shares of common stock at an exercise price of $4.36 per share on January 28, 2026.
The options are held directly and vest over time. One quarter of the award will vest on the first anniversary of January 28, 2026, with the remaining options vesting in substantially equal monthly installments over the following 36 months, contingent on continued service with the company.
Achieve Life Sciences, Inc. reported an insider equity grant for its Chief Legal Officer on a Form 4. On 12/04/2025, the officer received a stock option to purchase 250,000 shares of common stock at an exercise price of $4.78 per share. The option is exercisable as of 12/04/2025 and has an expiration date of 12/04/2035.
According to the footnote, this option will vest as to one quarter of the total award on the first anniversary of October 20, 2025, and the remaining portion will vest in substantially equal monthly installments over 36 months, subject to continued service with the company on each vesting date. Following this grant, the officer beneficially owns 250,000 derivative securities directly.
Achieve Life Sciences, Inc. (ACHV) reported an insider acquisition: Chief Operations Officer Craig Donnelly was granted a stock option on 10/01/2025 to purchase 50,000 shares of common stock at a $3.10 exercise price. The option vests with 1/4 of the award on the first anniversary of September 8, 2025 and then in substantially equal monthly installments over the following 36 months, subject to continued service. The Form 4 was signed by an attorney-in-fact on 10/03/2025. This filing documents a routine executive equity award that creates potential future dilution if exercised and ties the officer’s compensation to company share performance.
Mark K. Oki, Chief Financial Officer of Achieve Life Sciences, Inc. (ACHV), reported insider transactions on 09/18/2025. The filing shows settlement of 168,000 performance restricted stock units (PRSUs) into common stock, increasing his beneficial ownership to 178,000 shares immediately after settlement. Concurrently, the reporting person sold 50,060 shares in multiple transactions at a weighted average price of $2.92 per share (individual sale prices ranged from $2.83 to $3.02), reducing beneficial ownership to 127,940 shares. The PRSUs each represent a contingent right to one share and vest upon achievement of specified milestones; the related PRSUs list a date of 12/06/2028 in the filing. The sale is disclosed as made to satisfy income tax withholding and remittance obligations in connection with net settlement.
On September 18, 2025, Achieve Life Sciences CEO Stewart Richard Alistair settled performance restricted stock units into 297,500 shares of common stock and sold 129,501 shares at a weighted average price of $2.92 per share in transactions ranging from $2.83 to $3.02. After these transactions he holds 228,875 shares directly, plus 359 shares held by his spouse and 882 shares held through Ricanto Limited. Footnotes state that PRSUs each convert into one share upon milestone-based vesting and that some shares were sold to cover tax withholding on net settlement.